R-CHOP Chemotherapy for Disseminated Mycobacterium avium Complex Disease due to Anti-Interferon-Gamma Autoantibodies: A Case Report

Shunsuke Uno, Eisuke Uehara, Toshiki Kimura, Takuro Sakagami, Ho Namkoong, Sho Uchida, Yoshifumi Uwamino, Naoki Hasegawa

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

A 77-year-old Japanese man with disseminated Mycobacterium avium complex (MAC) disease due to anti-interferon-gamma autoantibodies received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy because of non-Hodgkin lymphoma complication. The hepatobiliary nodules due to MAC resolved with R-CHOP and multidrug antimycobacterial treatment. R-CHOP could serve as an alternative adjunctive therapy for patients with anti-interferon-gamma autoantibodies.

Original languageEnglish
Article numberofab181
JournalOpen Forum Infectious Diseases
Volume8
Issue number6
DOIs
Publication statusPublished - 2021 Jun 1

Keywords

  • R-CHOP
  • anti-interferon-gamma autoantibody
  • cyclophosphamide
  • disseminated Mycobacterium avium complex diseases
  • rituximab

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'R-CHOP Chemotherapy for Disseminated Mycobacterium avium Complex Disease due to Anti-Interferon-Gamma Autoantibodies: A Case Report'. Together they form a unique fingerprint.

Cite this